Cubist Systematic Strategies LLC Decreases Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Cubist Systematic Strategies LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 11.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,255 shares of the biotechnology company’s stock after selling 2,665 shares during the period. Cubist Systematic Strategies LLC owned about 0.09% of Enanta Pharmaceuticals worth $116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ENTA. China Universal Asset Management Co. Ltd. purchased a new stake in Enanta Pharmaceuticals in the 4th quarter valued at approximately $26,000. Tower Research Capital LLC TRC raised its position in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 2,274 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $58,000. Wells Fargo & Company MN raised its position in shares of Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 6,518 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $105,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Analyst Ratings Changes

ENTA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Up 7.1%

Shares of ENTA opened at $5.75 on Monday. The company’s fifty day moving average is $5.50 and its 200-day moving average is $6.59. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24. The firm has a market cap of $122.92 million, a price-to-earnings ratio of -1.16 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.